Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study

Max Lataillade, Jacob Lalezari, Michael D. Miller, Judith A. Aberg, Gilles Pialoux, Pedro Cahn, Melanie Thompson, Jean‐Michel Molina, Santiago Moreno, Beatriz Grinsztejn, Ricardo Sobhie Diaz, Antonella Castagna, Princy Kumar, Gulam Latiff, Edwin De Jesus, Marcia Wang, Shiven Chabria, Margaret Gartland, Amy Pierce, Peter Ackerman, Cyril Llamoso